ACCENDRA HEALTH INC/VA/ 8-K

What Happened
Accendra Health, Inc. (ACH) filed an 8-K on May 15, 2026 reporting results of its May 14, 2026 annual meeting. Shareholders elected six directors for one-year terms, ratified KPMG LLP as the company’s independent auditor for 2026, approved a non-binding advisory vote on executive compensation, and approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan (which restates the Owens & Minor, Inc. 2023 Omnibus Incentive Plan). The Board authorized its Our People & Culture Committee to grant equity and other incentive awards under the amended plan.

Key Details

• Voting turnout: 76,437,917 shares entitled to vote; 62,134,133 shares voted (~81.29% participation).
• Director elections (each elected to a one-year term): Mark A. Beck; Gwendolyn M. Bingham; Kenneth Gardner-Smith; Stephen W. Klemash; Teresa L. Kline; Edward A. Pesicka. Example vote totals: Mark A. Beck — 50,962,576 for / 1,294,183 against / 113,704 abstentions (9,763,670 broker non‑votes). Edward A. Pesicka received 48,760,777 for / 3,497,266 against / 112,420 abstentions.
• Amended and Restated 2023 Omnibus Incentive Plan approved: 50,645,557 for / 1,573,141 against / 151,765 abstentions (9,763,670 broker non‑votes). The plan authorizes equity and other incentive awards to employees, non‑employee directors and consultants.
• Ratification of auditor: KPMG LLP ratified for fiscal 2026 — 61,255,312 for / 693,111 against / 185,710 abstentions.
• Advisory vote on named executive officer compensation: passed — 48,137,834 for / 4,098,288 against / 134,341 abstentions.

Why It Matters

• The approved omnibus incentive plan lets Accendra grant stock and other awards to employees and directors, which can help retain and motivate management but may increase potential share dilution over time.
• Re-election of the incumbent board maintains current governance continuity; one director (Edward Pesicka) drew relatively higher opposition, which investors may note for governance dialogue.
• Ratifying KPMG ensures continuity in external audit coverage for 2026, and the advisory "say‑on‑pay" vote gives shareholders a non‑binding endorsement of executive compensation.